Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/09/2010US7829562 Therapy for stroke, cancer, brain disorders, multiple sclerosis, Huntington's disease; Parkinson's disease
11/09/2010US7829561 interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis
11/09/2010US7829560 such as N-(4-{[2-(4-Ethylpiperazin-1-yl)pyrimidin-4-yl]oxy}-1-naphthyl)-3-fluoro-5-piperidin-1-ylbenzamide, useful as antiproliferative agents or in treating arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, psoriasis, autoimmune or inflammatory diseases
11/09/2010US7829559 Substituted pyrazole sigma receptor antagonists
11/09/2010US7829558 Fused ring heterocycle kinase modulators
11/09/2010US7829557 2-heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer
11/09/2010US7829556 Sirtuin modulating compounds
11/09/2010US7829555 noncytotoxic bioreductive drug conjugates, used for targeting a therapeutic agent to a site of hypoxia and/or ischemia within the human or non-human animal body, suitable for the treatment of arthritis, diabetes, atherosclerosis, stroke, sepsis, cancer, Alzheimer's, kidney, digestive or liver disease
11/09/2010US7829554 contacting a targeted fat deposit with a formulation comprising long acting beta-2 adrenergic receptor agonist selected from salmeterol, formoterol and a glucocorticosteroid (e.g. dexamethasone, prednisolone, fluticasone, budesonid), a carrier, a excipient formulated for injection
11/09/2010US7829553 generation of NO from a C-based diazeniumdiolate that is covalently attached to a phenyl-containing polymer( polystyrene homo or copolymer, polyethyene terephthalate, polyamides etc.) without the possibility to form nitrosamines; of vascular stents, vascular grafts, catheters, wound dressings, bandages
11/09/2010US7829552 Phosphorus-containing thyromimetics
11/09/2010US7829551 Method and composition for the control of arthropods
11/09/2010US7829550 administering by inhalation to a asthma patient an effective dosage form of cyclodextrin selected from beta -cyclodextrin, hydroxypropyl- beta cyclodextrin, 2-O-methyl-cyclodextrin and sulfolbutylether- beta cyclodextrin
11/09/2010US7829549 Methods for treating bleeding disorders using sulfated polysaccharides
11/09/2010US7829548 the nucleoside 2',3'-dideoxy-3'-hydroxymethylcytidine or a prodrug; reverse transcriptase of the HIV bears a mutation that allows an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate; also with a NRTI
11/09/2010US7829546 applying an acid solution to the metal oxide substrate; mixing a solution containing the fine particles ( Au, Ag, Pt etc.) with a solution containing a self-organizing material (DNA, RNA, protein, Sugar, lipid); applying the mixed solution to the substrate after removing the acid solution, then drying
11/09/2010US7829545 Bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using alpha 1d-adrenergic receptor ( alpha 1dAR) antagonists. The invention further relates to a method of screening compounds
11/09/2010US7829544 Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
11/09/2010US7829543 Substituted polyamines as inhibitors of bacterial efflux pumps
11/09/2010US7829542 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
11/09/2010US7829536 administering to a patient with lymphedema a therapeutically effective amount of a vascular endothelial growth factor D (VEGF-D) protein at the site of edema, that binds and stimulates wild-type VEGFR-3; genetic disorders; screening
11/09/2010US7829535 for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors.
11/09/2010US7829534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
11/09/2010US7829530 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 by conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV; treating Type II diabetes but not sufficient to suppress the immune system of the animal
11/09/2010US7829518 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant
11/09/2010US7829503 Methods of identifying compounds that target tRNA splicing endonuclease and uses of said compounds as anti-fungal agents
11/09/2010US7829304 2-Amino-2-benzoyl-1-acetoxy-3-hydroxy- or 3-acetoxypropane tumor suppressor reactivators: 3-Acetoxy-2-(acetoxymethyl)-1-oxo-1-phenylpropan-2-ammonium chloride
11/09/2010US7829298 Human G protein-coupled receptors for metabolic-related disorders
11/09/2010US7829297 selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2 comprising determining whether the tumor expresses p95ErbB2; reversible dual tyrosine kinase inhibitor of both ErbB2 and epidermal growth factor receptor
11/09/2010US7829124 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/09/2010US7829123 Process
11/09/2010US7829122 Microgranules based on active principle and method for making same
11/09/2010US7829121 once-daily oral administration; FDA Orange book listed patent for cyclobenzaprine hydrochloride
11/09/2010US7829117 reaction product of polystyrene bound mesna (mercaptoethanesulfonic acid, sodium salt) and a sulfur-containing amino acid, preferably cysteine; chemical intermediates; anticarcinogenic agent; side effect reduction; heteroconjugate
11/09/2010US7829115 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
11/09/2010US7829114 Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
11/09/2010US7829112 Forming two drug permeable polymeric segments, exposing to preferential drug, connecting segments, delivering drug treatment; for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/09/2010US7829110 increasing tear resistance of scar tissue during wound repair by applying to a wound a surgical mesh comprising an anabolic steroid and a corticosteroid disposed in or on a surgical mesh structure
11/09/2010US7829107 drug delivery; skin disorders; supplying corticosteroid and fungicides
11/09/2010US7829100 vehicle comprising; a modified unsaturated oil and, optionally, a non-oxidizable oil; immediately after manufacture, composition can be administered such that the bioactive agents are released to the host on a predictable sustained basis.
11/09/2010US7829082 Catheter composition and uses thereof
11/09/2010US7829074 Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG
11/09/2010US7829073 Anhydrous cosmetic compositions comprising at least one polymeric gelling agent, at least one non-volatile oil, and poly(methyl methacrylate) particles
11/09/2010US7829068 0.1 to 4.5 wt. % dihydroxyacetone (DHA) incorporated in lamellae resulting from a mixture of phospholipids, lipids, organic solvents, water and DHA and prepared by a high-pressure homogenization process, 0.15 to 3.5 wt. % free dihydroxyacetone, phospholipids. alcoholic extracts from orange peel, tulips
11/09/2010US7829067 Method and composition for treating oral bacteria and inflammation
11/09/2010US7829065 Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents
11/09/2010US7828822 Spinous process implant
11/09/2010CA2624110C A rapidly-dissolving orally administrable wafer formulation
11/09/2010CA2620891C Use of n-(dibenz (b,f) oxepin-10ylmethyl)-n-methyl-n-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
11/09/2010CA2602198C Substituted triazole derivatives as oxytocin antagonists
11/09/2010CA2594684C Morpholines as 5ht2c agonists
11/09/2010CA2547283C Aminopyrazole derivatives as gsk-3 inhibitors
11/09/2010CA2540845C Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
11/09/2010CA2530140C Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
11/09/2010CA2496164C Benzimidazole quinolinones and uses thereof
11/09/2010CA2493958C Muscarinic agonists
11/09/2010CA2488279C Anti-inflammatory compositions derived from chicory
11/09/2010CA2484188C Tachykinin receptor antagonists
11/09/2010CA2479037C 2-amino-9[(2-hydroxymethyl)cyclopropylidenemethyl]purines as antiviral agents
11/09/2010CA2474563C Methods of inhibiting orthopoxvirus replication with nucleoside compounds
11/09/2010CA2462692C Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
11/09/2010CA2458209C Compositions comprising pectin and ascorbic acid
11/09/2010CA2438544C Aerosol compositions containing formoterol for delivery to the lungs via nebulization
11/09/2010CA2434937C Phenyl derivatives
11/09/2010CA2434028C Amino ceramide-like compounds and therapeutic methods of use
11/09/2010CA2430828C Pharmaceutical preparation comprising an active dispersed on a matrix
11/09/2010CA2421685C Soft tablet containing high molecular weight polyethylene oxide
11/09/2010CA2412899C Medicinal preparations for treating sex hormone-dependent diseases
11/09/2010CA2407659C Growth hormone secretagogues
11/09/2010CA2397583C New aminopropylphosphinic acids
11/09/2010CA2393487C Pharmaceutical preparation for the treatment of oncoses
11/09/2010CA2391983C Controlled-release dosage forms comprising zolpidem or a salt thereof
11/09/2010CA2380070C New derivatives of hydantoines, thiohydantoine, pyrimidinediones and thioxopyrimidinones, their preparation methods and their application as medications
11/09/2010CA2343102C Antisense modulation of survivin expression
11/09/2010CA2326654C Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
11/09/2010CA2315953C 3'-epimeric k-252a derivatives
11/09/2010CA2161684C Bioactive and/or targeted dendrimer conjugates
11/07/2010CA2665956A1 Combination treatment for ocular diseases
11/04/2010WO2010127363A1 Toposiomerase inhibitors
11/04/2010WO2010127360A1 Toposiomerase inhibitors
11/04/2010WO2010127346A1 Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
11/04/2010WO2010127313A1 Hmg-coa secondary metabolites and uses thereof
11/04/2010WO2010127307A1 Antimicrobial agents
11/04/2010WO2010127271A1 Polymer micelles containing anthracylines for the treatment of cancer
11/04/2010WO2010127264A2 HNF4α ANTAGONISTS AND METHODS OF USE
11/04/2010WO2010127250A1 Chewing gum composition, chewing gum product, and method for manufacturing same
11/04/2010WO2010127246A2 Hnf4 modulators and methods of use
11/04/2010WO2010127235A1 Schweinfurthins and uses thereof
11/04/2010WO2010127231A2 Moisturizing antimicrobial composition
11/04/2010WO2010127212A1 Inhibitors of acetyl-coa carboxylase
11/04/2010WO2010127210A1 Method of reducing intraocular pressure in humans
11/04/2010WO2010127209A2 Compositions and methods for therapy of macular degeneration
11/04/2010WO2010127208A1 Inhibitors of acetyl-coa carboxylase
11/04/2010WO2010127205A2 Fixed dose drug combination formulations
11/04/2010WO2010127198A1 Formulation for oral administration of apoptosis promoter
11/04/2010WO2010127197A2 Method and composition for treating diabetic ketoacidosis
11/04/2010WO2010127193A1 Stabilized lipid formulation of apoptosis promoter
11/04/2010WO2010127192A1 Lipid formulation of apoptosis promoter
11/04/2010WO2010127191A1 Solid oral formulation of abt-263
11/04/2010WO2010127190A1 Salt of abt-263 and solid-state forms thereof
1 ... 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 ... 7860